Adverse cardiovascular and kidney outcomes in people with SARS-CoV-2 treated with SGLT2 inhibitors
Abstract Background Whether use of SGLT2 inhibitors reduces the risk of cardiovascular and kidney events in people who contracted SARS-CoV-2 infection is not clear. Methods We used the healthcare databases of the United States Department of Veterans Affairs to build a cohort of 107,776 participants...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-09-01
|
| Series: | Communications Medicine |
| Online Access: | https://doi.org/10.1038/s43856-024-00599-4 |